Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended

2022-502661-23-00 Relapsed/refractory B-cell non-Hodgkin lymphoma 7 2024-06-11
TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended

2023-508212-38-00 Multiple Myeloma 4 2024-06-11
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended

2023-506054-20-00 Adenocarcinoma of the biliary tract (intrahepatic or ex 5 2024-06-05
ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRE… Ended

2023-508615-24-00 Patients affected by mCRC harbouring BRAF V600E 4 2024-06-03
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate) Ended

2023-509486-20-00 Breast cancer 10 2024-05-29
A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar… Ended

2023-508459-37-00 HER2-positive advanced solid tumours 1 2024-05-28
A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended

2023-507995-33-00 MSI-H/dMMR Gastric cancer 9 2024-05-23
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended

2023-506906-38-00 Follicular Lymphoma 5 2024-05-23
Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended

2023-503755-10-00 Splenic marginal zone lymphoma 5 2024-05-17
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurr… Ended

2022-502134-10-00 Glioblastoma 3 2024-05-15
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended

2023-507516-12-00 Solid Tumors 4 2024-05-08
A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended

2022-501234-37-00 Solid Tumours 7 2024-05-07
Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to … Ended

2024-513141-37-00 Recurrent or progression of neuroblastoma or neuroblast 5 2024-05-06
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3 Ended

2022-501766-22-01 Glioma expressing DLL3 3 2024-04-23
A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended

2023-505658-17-00 Muscle-invasive Urothelial Carcinoma 4 2024-04-16
A trial to learn if taking osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell … Ended

2023-507798-16-00 Unresectable Non-small Cell Lung Cancer 4 2024-04-16
TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer Ended

2023-505722-33-00 cholangiocarcinoma or gallbladder carcinoma 4 2024-04-15
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent gl… Ended

2023-508278-26-01 glioblastoma 7 2024-04-05